As biosimilar competition to Herceptin ramps up, Roche is looking to bolster its position in HER2-positive breast cancer with a new indication for Kadcyla.
The FDA has approved a new biosimilar of Roche’s breast cancer drug Herceptin, from Samsung Bioepis and Merck & Co, ahead of the original drug’s US patent expiry in June.
Angle’s liquid biopsy system has been used in new cancer research that could provide a novel way to treat breast cancer and other tumours, by stopping or suppressing their spread from the o
